Kerala Ayurveda Quarterly Results for Trading Insights
In Mar 2026, Kerala Ayurveda (KERALAYUR) reported revenue ₹37 Cr and net profit ₹-7 Cr — revenue +15.6% YoY. Compare with KERALAYUR fair value estimate to assess whether the stock is under or overvalued.
KERALAYUR Quarterly Results — Revenue, Profit & EPS Highlights
Kerala Ayurveda latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit KERALAYUR share price screener.
- Revenue of ₹37 Cr in Mar 2026 (+0.0% vs Sept 2025, +15.6% vs Mar 2025)
- Net Profit of ₹-7 Cr in Mar 2026 (-16.7% vs Sept 2025, +53.3% vs Mar 2025)
- EBITDA of ₹-5 Cr in Mar 2026 (-66.7% vs Sept 2025)
- Operating Margin of -20.0% in Mar 2026 (-6.0pp vs Sept 2025)
- Earnings Per Share of ₹-5.83 in Mar 2026 (+19.4% vs Sept 2025)
Kerala Ayurveda Quarterly Results — Revenue, EBITDA, Net Profit & EPS
KERALAYUR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 37 | 37 | 32 | 38 | 34 | - | 15.6% |
| Net Profit (₹ Cr) | -7 | -6 | -15 | 2 | -5 | - | - |
| EBITDA (₹ Cr) | -5 | -3 | -9 | 5 | 0 | - | - |
| EPS (₹) | -5.83 | -7.23 | -12.78 | 1.92 | -3.81 | - | - |
| Operating Margin (%) | -20.0% | -14.0% | -32.0% | -15.0% | -5.0% | - | - |
KERALAYUR Share Price Trend — 1-Year Movement Across Quarterly Results
Kerala Ayurveda 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore KERALAYUR share price charts to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
KERALAYUR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Kerala Ayurveda latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1862.9 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 164.9 |
|
Divis Laboratories
Mar 2026 |
₹175,434.91 Cr | 6787.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 239.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹149,924.56 Cr | 4457.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 387.2 |
|
Zydus Life Science
Mar 2026 |
₹109,226.70 Cr | 1085.5 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 85.8 |
|
Cipla
Mar 2026 |
₹109,195.79 Cr | 1415.7 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.1 |
All amounts in ₹ Crores